A Phase Ib/II study of pembrolizumab, ibrutinib and rituximab in recurrent central nervous system lymphoma (CNSL)
Study of Pembrolizumab, Ibrutinib and Rituximab in Patients with Primary Central Nervous System Lymphoma (PCNSL)
Sponsor: NA
Enrolling: Male and Female Patients
IRB Number: AAAT7683
U.S. Govt. ID: NCT04421560
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses including other types of non-Hodgkins lymphoma.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with primary central nervous system lymphoma (PCNSL)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator